These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27342050)

  • 21. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.
    Shrestha B; Ng T; Chu HJ; Noll M; Diamond MS
    Vaccine; 2008 Apr; 26(16):2020-33. PubMed ID: 18339459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge.
    Karaca K; Bowen R; Austgen LE; Teehee M; Siger L; Grosenbaugh D; Loosemore L; Audonnet JC; Nordgren R; Minke JM
    Vaccine; 2005 May; 23(29):3808-13. PubMed ID: 15893618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Replication-Defective West Nile Virus with NS1 Deletion as a New Vaccine Platform for Flavivirus.
    Li N; Zhang YN; Deng CL; Shi PY; Yuan ZM; Zhang B
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
    Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
    Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.
    Chaintoutis SC; Diakakis N; Papanastassopoulou M; Banos G; Dovas CI
    Clin Vaccine Immunol; 2015 Sep; 22(9):1040-9. PubMed ID: 26178384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum neutralising antibody titres against a lineage 2 neuroinvasive West Nile Virus strain in response to vaccination with an inactivated lineage 1 vaccine in a European endemic area.
    Fehér O; Bakonyi T; Barna M; Nagy A; Takács M; Szenci O; Joó K; Sárdi S; Korbacska-Kutasi O
    Vet Immunol Immunopathol; 2020 Sep; 227():110087. PubMed ID: 32629300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.
    Schepp-Berglind J; Luo M; Wang D; Wicker JA; Raja NU; Hoel BD; Holman DH; Barrett AD; Dong JY
    Clin Vaccine Immunol; 2007 Sep; 14(9):1117-26. PubMed ID: 17634508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. West Nile virus-specific immunoglobulin isotype responses in vaccinated and infected horses.
    Khatibzadeh SM; Gold CB; Keggan AE; Perkins GA; Glaser AL; Dubovi EJ; Wagner B
    Am J Vet Res; 2015 Jan; 76(1):92-100. PubMed ID: 25535666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine.
    Grosenbaugh DA; Backus CS; Karaca K; Minke JM; Nordgren RM
    Vet Ther; 2004; 5(4):251-7. PubMed ID: 15719324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE).
    Escribano-Romero E; Gamino V; Merino-Ramos T; Blázquez AB; Martín-Acebes MA; de Oya NJ; Gutiérrez-Guzmán AV; Escribano JM; Höfle U; Saiz JC
    Vaccine; 2013 Sep; 31(41):4523-7. PubMed ID: 23933372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A recombinant novirhabdovirus presenting at the surface the E Glycoprotein from West Nile Virus (WNV) is immunogenic and provides partial protection against lethal WNV challenge in BALB/c mice.
    Nzonza A; Lecollinet S; Chat S; Lowenski S; Mérour E; Biacchesi S; Brémont M
    PLoS One; 2014; 9(3):e91766. PubMed ID: 24663075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.
    Goo L; Debbink K; Kose N; Sapparapu G; Doyle MP; Wessel AW; Richner JM; Burgomaster KE; Larman BC; Dowd KA; Diamond MS; Crowe JE; Pierson TC
    Nat Microbiol; 2019 Jan; 4(1):71-77. PubMed ID: 30455471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis.
    Watts DM; Tesh RB; Siirin M; Rosa AT; Newman PC; Clements DE; Ogata S; Coller BA; Weeks-Levy C; Lieberman MM
    Vaccine; 2007 Apr; 25(15):2913-8. PubMed ID: 17067727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.
    Martin JE; Pierson TC; Hubka S; Rucker S; Gordon IJ; Enama ME; Andrews CA; Xu Q; Davis BS; Nason M; Fay M; Koup RA; Roederer M; Bailer RT; Gomez PL; Mascola JR; Chang GJ; Nabel GJ; Graham BS
    J Infect Dis; 2007 Dec; 196(12):1732-40. PubMed ID: 18190252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.
    Gershoni-Yahalom O; Landes S; Kleiman-Shoval S; Ben-Nathan D; Kam M; Lachmi BE; Khinich Y; Simanov M; Samina I; Eitan A; Cohen IR; Rager-Zisman B; Porgador A
    Immunology; 2010 Aug; 130(4):527-35. PubMed ID: 20331473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baboon model for West Nile virus infection and vaccine evaluation.
    Wolf RF; Papin JF; Hines-Boykin R; Chavez-Suarez M; White GL; Sakalian M; Dittmer DP
    Virology; 2006 Nov; 355(1):44-51. PubMed ID: 16904151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycoprotein-C-gene-deleted recombinant infectious laryngotracheitis virus expressing a genotype VII Newcastle disease virus fusion protein protects against virulent infectious laryngotracheitis virus and Newcastle disease virus.
    Wei X; Shao Y; Han Z; Sun J; Liu S
    Vet Microbiol; 2020 Nov; 250():108835. PubMed ID: 33011664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
    McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
    J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge.
    Minke JM; Siger L; Karaca K; Austgen L; Gordy P; Bowen R; Renshaw RW; Loosmore S; Audonnet JC; Nordgren B
    Arch Virol Suppl; 2004; (18):221-30. PubMed ID: 15119777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.